Why Viking Therapeutics (VKTX) Is Down 6.5% After Publishing VK2735 Phase 2 Obesity Trial Results And What's Next [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
in a Phase 2 trial, meeting primary and secondary endpoints and supporting progression into the large Phase 3 VANQUISH-1 study with about 4,650 patients enrolled. The publication of these data in a peer-reviewed journal, combined with management's characterization of VK2735 as a potentially best-in-class dual GLP-1/GIP agonist, underscores Viking's ambition to challenge established players in the fast-growing obesity treatment market. Next, we'll examine how the promising VK2735 Phase 2 results and rapid Phase 3 enrollment shape Viking Therapeutics' investment narrative. Uncover the next big thing with financially sound penny stocks that balance risk and reward For someone owning Viking Therapeutics, the crux of the story is clear: you have to believe VK2735 can eventually translate strong clinical data into an approved, commercially relevant obesity treatment, despite the company having no revenue today and ongoing losses of roughly US$237.4 million. The January 2026 publicat
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- 2 Biotech Stocks Set to Rebound in 2026 [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline [Yahoo! Finance]Yahoo! Finance
- The Best Stocks to Invest $40 in to Start the New Year Off Right [Yahoo! Finance]Yahoo! Finance
- Assessing Viking Therapeutics (VKTX) Valuation As Shares Rebound Over The Past Week [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics (NASDAQ:VKTX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Analyst Actions
- 11/12/25 - Canaccord Genuity
VKTX
Sec Filings
- 1/26/26 - Form 4
- 1/26/26 - Form 3
- 1/5/26 - Form 4
- VKTX's page on the SEC website